These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 17300920)
1. An intervention programme for the management of multidrug-resistant tuberculosis in France. Uffredi ML; Truffot-Pernot C; Dautzenberg B; Renard M; Jarlier V; Robert J Int J Antimicrob Agents; 2007 Apr; 29(4):434-9. PubMed ID: 17300920 [TBL] [Abstract][Full Text] [Related]
2. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Pablos-Mendez A; Gowda DK; Frieden TR Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008 [TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154 [TBL] [Abstract][Full Text] [Related]
4. Management of multi-drug resistant tuberculosis: practitioner's view point. Prasad R Indian J Tuberc; 2007 Jan; 54(1):3-11. PubMed ID: 17455417 [TBL] [Abstract][Full Text] [Related]
5. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Park SK; Kim JH; Kang H; Cho JS; Smego RA Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342 [TBL] [Abstract][Full Text] [Related]
6. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Palmero DJ; Ambroggi M; Brea A; De Lucas M; Fulgenzi A; Martínez D; Mosca C; Musella R; Natiello M; Gonzalez C; Abbate E Int J Tuberc Lung Dis; 2004 Jun; 8(6):778-84. PubMed ID: 15182150 [TBL] [Abstract][Full Text] [Related]
7. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823 [TBL] [Abstract][Full Text] [Related]
8. Representative drug susceptibility patterns for guiding design of re-treatment regimens for multidrug-resistant tuberculosis in Iran. Tabarsi P; Nooraki A; Mirsaeidi M; Amiri M; Baghaei P; Farnia P; Kazempour M; Heidarnazhad H; Alipanah N; Mansouri D; Masjedi MR Respirology; 2008 Jan; 13(1):108-11. PubMed ID: 18197919 [TBL] [Abstract][Full Text] [Related]
9. Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme. Quelapio MI; Mira NR; Orillaza-Chi RB; Belen V; Muñez N; Belchez R; Egos GE; Evangelista M; Vianzon R; Tupasi TE Int J Tuberc Lung Dis; 2010 Jun; 14(6):751-7. PubMed ID: 20487615 [TBL] [Abstract][Full Text] [Related]
10. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006. Masjedi MR; Tabarsi P; Chitsaz E; Baghaei P; Mirsaeidi M; Amiri MV; Farnia P; Javanmard P; Mansouri D; Velayati AA Int J Tuberc Lung Dis; 2008 Jul; 12(7):750-5. PubMed ID: 18544199 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus. Ollé-Goig JE; Sandy R Int J Tuberc Lung Dis; 2005 Jul; 9(7):765-70. PubMed ID: 16013772 [TBL] [Abstract][Full Text] [Related]
12. Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study. Tabarsi P; Baghaei P; Jalali S; Farnia P; Chitsaz E; Mirsaeidi M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA Scand J Infect Dis; 2009; 41(1):10-3. PubMed ID: 19037820 [TBL] [Abstract][Full Text] [Related]
14. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Flament-Saillour M; Robert J; Jarlier V; Grosset J Am J Respir Crit Care Med; 1999 Aug; 160(2):587-93. PubMed ID: 10430733 [TBL] [Abstract][Full Text] [Related]
15. Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Escudero E; Peña JM; Alvarez-Sala R; Vázquez JJ; Ortega A Int J Tuberc Lung Dis; 2006 Apr; 10(4):409-14. PubMed ID: 16602405 [TBL] [Abstract][Full Text] [Related]
16. In vitro drug resistance and response to therapy in pulmonary tuberculosis patients under a DOTS programme in south India. Aparna SB; Reddy VC; Gokhale S; Moorthy KV Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):564-70. PubMed ID: 19243801 [TBL] [Abstract][Full Text] [Related]
17. Management of multi drug resistance tuberculosis in the field: Tuberculosis Research Centre experience. Thomas A; Ramachandran R; Rehaman F; Jaggarajamma K; Santha T; Selvakumar N; Krishnan N; Mohan NS; Sundaram V; Wares F; Narayanan PR Indian J Tuberc; 2007 Jul; 54(3):117-24. PubMed ID: 17886699 [TBL] [Abstract][Full Text] [Related]
18. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance. Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897 [TBL] [Abstract][Full Text] [Related]
19. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients--a trend. Rajasekaran S; Chandrasekar C; Mahilmaran A; Kanakaraj K; Karthikeyan DS; Suriakumar J J Indian Med Assoc; 2009 May; 107(5):281-2, 284-6. PubMed ID: 19886382 [TBL] [Abstract][Full Text] [Related]
20. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis]. Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]